This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [¹⁸F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.

该联合实践指南/程序标准由欧洲核医学协会 （EANM）、核医学和分子影像学会 （SNMMI）、欧洲神经肿瘤学协会 （EANO） 和神经肿瘤学反应评估工作组 （PET/RANO） 的 PET 工作组合作制定。脑转移瘤是最常见的恶性中枢神经系统 （CNS） 肿瘤。放射性标记氨基酸和较小程度的 [¹⁸F]FDG 的 PET 成像在脑转移的评估中越来越重要，尤其是对于复发性转移和治疗相关变化之间的鉴别诊断，这仍然是传统 MRI 的一个局限性。本指南的目的是协助核医学医生推荐、实施、解释和报告脑转移患者的脑 PET 成像结果。本实践指南将定义在常规实践和临床试验中脑转移患者中应用 PET 成像的程序标准，并将有助于协调跨中心的数据采集和解释。